Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis’ Tekturna faces three month delay

Executive Summary

FDA extends its review of Novartis' NDA for its potential first-in-class oral rennin inhibitor Tekturna (aliskiren) by three months, the company announces Dec. 14. A delay was expected after Novartis said during its R&D day that it was submitting additional data to FDA about the antihypertensive's impact on the colon (1"The Pink Sheet" Dec. 11, 2005, p. 10). Novartis filed aliskiren for both single agent and combination treatment of high blood pressure in the first quarter, setting a late December user fee date. A review extension for Tekturna is the second regulatory setback for Novartis in recent months; the firm announced Nov. 13 that FDA extended the review period for the DPP-4 diabetes agent Galvus (vildagliptin) by three months to assess dermatologic toxicity (2"The Pink Sheet" Dec. 4, 2006, p. 9)...
Advertisement
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

PS047851

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel